Skip to main content

Advertisement

SpringerLink
Log in

ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

Recent studies on gliomas have shown frequent alterations in the alpha-thalassemia/mental retardation syndrome X-linked gene (ATRX). This study was designed to determine whether ATRX status correlates with uptake of 11C-methionine in WHO grades II and III gliomas. Sixty-two patients underwent 11C-methionine positron emission tomography scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of 11C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. After surgery, tumor samples were subjected to immunohistochemistry for ATRX and IDH1-R132H followed by IDH1/2 sequencing. Twenty-seven of the sixty-two patients were found to have the IDH mutation. Nine of the twenty-seven gliomas harboring IDH mutations exhibited loss of nuclear ATRX expression, which is accompanied with an astrocytic tumor lineage and a poor prognosis. The mean T/N ratio in tumors with loss of nuclear ATRX expression was 2.20 ± 0.53, i.e., significantly lower than that of tumors with ATRX retention (3.28 ± 1.32, p = 0.0171, U test). Our study showed ATRX status to correlate with the T/N ratio and the outcomes of WHO grade II and III glioma patients with the IDH1 mutation. Our data provide new information on the biology and imaging characteristics of gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498

    Article  Google Scholar 

  2. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820

    Article  PubMed  Google Scholar 

  3. Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468

    Article  CAS  PubMed  Google Scholar 

  4. Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625

    Article  CAS  PubMed  Google Scholar 

  5. Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722

    Article  PubMed  PubMed Central  Google Scholar 

  6. Saito T, Maruyama T, Muragaki Y et al (2013) 11 C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol 34:85–91

    Article  CAS  PubMed  Google Scholar 

  7. Iwadate Y, Shinozaki N, Matsutani T et al (2016) Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11 C-methionine positron emission tomography. J Neurol Neurosurg Psychiatry 87:1016–1021

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474

    Article  PubMed  Google Scholar 

  9. Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451

    Article  CAS  PubMed  Google Scholar 

  10. Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146

    Article  CAS  PubMed  Google Scholar 

  11. Nojiri T, Nariai T, Aoyagi M et al (2009) Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93:233–241

    Article  CAS  PubMed  Google Scholar 

  12. Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507

    Article  PubMed  Google Scholar 

  13. Shinozaki N, Uchino Y, Yoshikawa K et al (2011) Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11 C-methionine positron emission tomography. J Neurosurg 114:1640–1647

    Article  PubMed  Google Scholar 

  14. Louis DN, Ohgaki H, Wiestler OD et al (2007) World Health Organization histological classi cation of tumours of the central nervous system. International Agency for Research on Cancer, Lyon

    Google Scholar 

  15. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458

    Article  CAS  PubMed  Google Scholar 

  16. Ishiwata K, Kubota K, Murakami M et al (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34:1936–1943

    CAS  PubMed  Google Scholar 

  17. Langen KJ, Muhlensiepen H, Holschbach M et al (2000) Transport mechanisms of 3-[123I]iodo-alpha-methyl-l-tyrosine in a human glioma cell line: comparison with [3H]methyl]-l-methionine. J Nucl Med 41:1250–1255

    CAS  PubMed  Google Scholar 

  18. Bergstrom M, Lundqvist H, Ericson K et al (1987) Comparison of the accumulation kinetics of l-(methyl-11C)-methionine and d-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 28:225–229

    CAS  PubMed  Google Scholar 

  19. Wienhard K, Herholz K, Coenen HH et al (1991) Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 32:1338–1346

    CAS  PubMed  Google Scholar 

  20. Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273

    PubMed  Google Scholar 

  21. Lee JC, Jeng YM, Liau JY et al (2015) Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol 28:1064–1073

    Article  CAS  PubMed  Google Scholar 

  22. Marinoni I, Kurrer AS, Vassella E et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146(453–460):e455

    Google Scholar 

  23. Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ikemura M, Shibahara J, Mukasa A et al (2016) Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69:260–267

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. Hiroaki Wakimoto (Harvard University, Boston) for invaluable advice. This work was supported by JSPS KAKENHI Grant Number 15K19954 (K. Tamura). Portions of this study were presented in abstract form at the 34th Annual Meeting of the Japan Society of Brain Tumor Pathology, Tokyo, Japan, May 27, 2016.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Takahiro Ogishima, Kaoru Tamura, Motoki Inaji, Shihori Hayashi, Tadashi Nariai & Taketoshi Maehara

  2. Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan

    Daisuke Kobayashi & Reina Tamura

  3. Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

    Motoki Inaji, Shihori Hayashi, Tadashi Nariai & Kenji Ishii

Authors
  1. Takahiro Ogishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaoru Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Motoki Inaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shihori Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reina Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tadashi Nariai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenji Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Taketoshi Maehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaoru Tamura.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

This study was approved by the Ethics Committee of the Tokyo Medical and Dental University. Informed consent was obtained from the patients and/or their guardians.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogishima, T., Tamura, K., Kobayashi, D. et al. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Brain Tumor Pathol 34, 20–27 (2017). https://doi.org/10.1007/s10014-017-0280-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-017-0280-1

Keywords

Search

Navigation